- Pharmanovia acquires 11 CNS brands, including Frisium® (clobazam) and Gardenal® (phenobarbital)

- The portfolio is available in more than 60 markets and reinforces our presence in Brazil, South Africa, France and Italy

• The SNC's solid franchise fits with Pharmanovia's current portfolio of neurology and commercial capabilities

The brands cover four therapeutic areas with unmet needs associated with CNS disorders: psycholeptic, anxiolytic, antiepileptic and antipsychotic.

Clobazam belongs to a class of drugs called benzodiazepines and can be used to treat anxiety, with or without insomnia or certain psychiatric conditions, in certain patients.¹ The brands purchased include Frisium®, Sentil®, Urbanyl®, Urbanil®, Urbanol®, Urbadan®, Noiafren® and Castilium®*. Frisium® can also be used as a complementary treatment for epilepsy.¹

Phenobarbital (brand: Gardenal®*) is used as an anticonvulsant to treat all forms of epilepsy except absence seizures.²

Ciamemazine (brand: Tercian®*†) is used to treat certain types of psychotic disorders, anxiety in patients in whom other treatments failed and also some types of depression in combination with another antidepressant.³

Prochlorperazine (brand: Stemetil®*) is used to treat vertigo and nausea and vomiting caused by various causes. It can also be used to treat other conditions such as schizophrenia, acute mania and as a complement to the short-term treatment of anxiety.^4,5

Dr. James Burt, CEO of Pharmanovia, commented the following: "Sanofi's decision to transfer to Pharmanovia this consolidated portfolio of products for the CNS, with leading brands such as Frisium® and Gardenal®, is a recognition of our experience in neurology, our abilities in life cycle management and our reputation as a trusted divestment partner. We are excited to use this knowledge and our global platform to ensure that these important medicines not only remain available to the millions of patients who need them, but that, through our life cycle management, they continue to evolve to meet the needs of patients."

"Through this acquisition, we are not only deepening the geography, but we are also bringing products that have a clear synergy with our existing portfolio and the central subtherapeutic foci of mental health and epilepsy, where there is still an important unmet need."